{"id":90115,"date":"2026-05-18T17:19:23","date_gmt":"2026-05-18T11:49:23","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=90115"},"modified":"2026-05-18T17:19:25","modified_gmt":"2026-05-18T11:49:25","slug":"alembic-pharmaceuticals-q4-fy26-results","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/alembic-pharmaceuticals-q4-fy26-results\/","title":{"rendered":"Alembic Pharmaceuticals Q4 FY26 Results: PAT Rs 202 Cr, Revenue Rs 1,848 Crore"},"content":{"rendered":"<div class=\"meta-block\"><\/div>\n<p><strong><a href=\"_wp_link_placeholder\" data-wplink-edit=\"true\">Alembic Pharmaceuticals<\/a> Q4 FY26<\/strong> results were declared on May 15, 2026, at the board of directors meeting. Alembic Pharmaceuticals reported PAT of Rs 202 crore for the quarter ended March 31, 2026, up 28.7% YoY from Rs 157 crore in Q4 FY25, on revenue of Rs 1,848 crore. Alembic Pharmaceuticals is a pharmaceutical formulations and APIs company. Investors tracking Alembic Pharmaceuticals Q4 FY26 will find complete financial analysis, segment performance, and FY27 outlook in this article.<\/p>\n<p><a href=\"https:\/\/univest.in\/user\/log-in\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/alembic-pharmaceuticals-q4-fy26-results\/#Alembic_Pharmaceuticals_Q4_FY26_Financial_Highlights\" title=\"Alembic Pharmaceuticals Q4 FY26 Financial Highlights\">Alembic Pharmaceuticals Q4 FY26 Financial Highlights<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/alembic-pharmaceuticals-q4-fy26-results\/#Alembic_Pharmaceuticals_Q4_FY26_Performance_Analysis\" title=\"Alembic Pharmaceuticals Q4 FY26 Performance Analysis\">Alembic Pharmaceuticals Q4 FY26 Performance Analysis<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/alembic-pharmaceuticals-q4-fy26-results\/#Key_Business_Factors_for_Alembic_Pharmaceuticals_Q4_FY26\" title=\"Key Business Factors for Alembic Pharmaceuticals Q4 FY26\">Key Business Factors for Alembic Pharmaceuticals Q4 FY26<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/alembic-pharmaceuticals-q4-fy26-results\/#Sectoral_Demand_and_Revenue_Momentum\" title=\"Sectoral Demand and Revenue Momentum\">Sectoral Demand and Revenue Momentum<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/alembic-pharmaceuticals-q4-fy26-results\/#Margin_and_Profitability_Outlook\" title=\"Margin and Profitability Outlook\">Margin and Profitability Outlook<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/alembic-pharmaceuticals-q4-fy26-results\/#FY27_Guidance_and_Business_Outlook\" title=\"FY27 Guidance and Business Outlook\">FY27 Guidance and Business Outlook<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/alembic-pharmaceuticals-q4-fy26-results\/#Frequently_Asked_Questions_on_Alembic\" title=\"Frequently Asked Questions on Alembic\">Frequently Asked Questions on Alembic<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/alembic-pharmaceuticals-q4-fy26-results\/#What_is_the_company_PAT\" title=\"What is the company PAT?\">What is the company PAT?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/alembic-pharmaceuticals-q4-fy26-results\/#What_is_the_companys_revenue\" title=\"What is the company&#8217;s revenue?\">What is the company&#8217;s revenue?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/alembic-pharmaceuticals-q4-fy26-results\/#When_were_Alembic_results_announced\" title=\"When were Alembic results announced?\">When were Alembic results announced?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/alembic-pharmaceuticals-q4-fy26-results\/#What_sector_does_Alembic_Pharmaceuticals_operate_in\" title=\"What sector does Alembic Pharmaceuticals operate in?\">What sector does Alembic Pharmaceuticals operate in?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/alembic-pharmaceuticals-q4-fy26-results\/#Is_Alembic_Pharmaceuticals_a_good_investment_after_Q4_FY26\" title=\"Is Alembic Pharmaceuticals a good investment after Q4 FY26?\">Is Alembic Pharmaceuticals a good investment after Q4 FY26?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Alembic_Pharmaceuticals_Q4_FY26_Financial_Highlights\"><\/span><strong>Alembic Pharmaceuticals Q4 FY26 Financial Highlights<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<tbody>\n<tr>\n<th>Metric<\/th>\n<th>Q4 FY26<\/th>\n<th>Comparison<\/th>\n<\/tr>\n<tr>\n<td><strong>PAT (Net Profit)<\/strong><\/td>\n<td>Rs 202 crore<\/td>\n<td>up 28.7% YoY from Rs 157 crore in Q4 FY25<\/td>\n<\/tr>\n<tr>\n<td><strong>Revenue from Operations<\/strong><\/td>\n<td>Rs 1,848 crore<\/td>\n<td>Q4 FY26 (quarter ended March 31, 2026)<\/td>\n<\/tr>\n<tr>\n<td><strong>Ticker<\/strong><\/td>\n<td>APLLTD<\/td>\n<td>Sector: Pharmaceuticals<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Alembic_Pharmaceuticals_Q4_FY26_Performance_Analysis\"><\/span><strong>Alembic Pharmaceuticals Q4 FY26 Performance Analysis<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Alembic Pharmaceuticals Q4 FY26 results reflect the company&#8217;s operational performance during the January to March 2026 quarter. Alembic Pharmaceuticals operates in the pharmaceutical formulations and APIs space, a sector that has seen strong demand tailwinds in FY26 driven by domestic consumption growth, government capex, and India&#8217;s infrastructure buildout. The Q4 results cap the full FY26 year and set the baseline for FY27 guidance.<\/p>\n<p>The quarter&#8217;s profitability improvement reflects better operating leverage, pricing discipline, and cost management. Investors tracking Alembic Pharmaceuticals Q4 FY26 will monitor FY27 revenue visibility and management commentary on margin sustainability. Track Alembic Pharmaceuticals on the Univest Screener for live data and analyst ratings.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Business_Factors_for_Alembic_Pharmaceuticals_Q4_FY26\"><\/span><strong>Key Business Factors for Alembic Pharmaceuticals Q4 FY26<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Sectoral_Demand_and_Revenue_Momentum\"><\/span><strong>Sectoral Demand and Revenue Momentum<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Alembic revenue of Rs 1,848 crore reflects the company&#8217;s ability to execute in a competitive pharmaceutical formulations and APIs environment. Q4 is typically the strongest quarter for most Indian companies as year-end government spending, project completions, and festival-driven demand peak. The revenue trajectory for FY27 will be determined by order book conversions, new contract wins, and demand visibility from key customers.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Margin_and_Profitability_Outlook\"><\/span><strong>Margin and Profitability Outlook<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The company PAT of Rs 202.0 crore reflects profitable operations with improving margins across the business. EBITDA margin trends and operating leverage will be key metrics to watch as FY27 guidance is finalised.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"FY27_Guidance_and_Business_Outlook\"><\/span><strong>FY27 Guidance and Business Outlook<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Following the firm results, management commentary on FY27 revenue guidance, capital expenditure plans, dividend policy, and strategic priorities will be the key near-term catalysts for the stock. India&#8217;s robust GDP growth of 6.5%+ and the government&#8217;s sustained infrastructure and consumption push create a positive macro backdrop for FY27 across most sectors. Monitor Alembic Pharmaceuticals financials in real time on the Univest Screener.<\/p>\n<p><a href=\"https:\/\/univest.in\/screeners\"><strong>Check the Univest Screener for live data<\/strong><\/a><\/p>\n<p>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track live prices and SEBI-registered analyst research.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions_on_Alembic\"><\/span><strong>Frequently Asked Questions on Alembic<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_company_PAT\"><\/span><strong>What is the company PAT?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Alembic reported PAT of Rs 202 crore up 28.7% YoY from Rs 157 crore in Q4 FY25. Results were declared on May 15, 2026. Full details are available from NSE\/BSE regulatory filings. Verify all numbers before investing.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_companys_revenue\"><\/span><strong>What is the company&#8217;s revenue?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong style=\"color: initial;\">Ans.<\/strong><span style=\"color: initial;\"> The firm&#8217;s revenue from operations was Rs 1,848 crore for the quarter ended March 31, 2026.<\/span>\u00a0Track real-time financials on the Univest Screener.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"When_were_Alembic_results_announced\"><\/span><strong>When were Alembic results announced?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The company results were announced on May 15, 2026, at the board of directors meeting approving audited financial statements for Q4 and the full year ended March 31, 2026.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_sector_does_Alembic_Pharmaceuticals_operate_in\"><\/span><strong>What sector does Alembic Pharmaceuticals operate in?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Alembic Pharmaceuticals operates in the pharmaceutical formulations and APIs sector. Download the Univest iOS App or Univest Android App to track Alembic Pharmaceuticals and get SEBI-registered research.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Alembic_Pharmaceuticals_a_good_investment_after_Q4_FY26\"><\/span><strong>Is Alembic Pharmaceuticals a good investment after Q4 FY26?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Investment decisions should be based on a comprehensive analysis of fundamentals, sector dynamics, valuation, and individual risk appetite. This article does not constitute investment advice. Consult a SEBI-registered financial advisor before investing. This content is for educational purposes only.<\/p>\n<p><em>Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Alembic Pharmaceuticals Q4 FY26 results May 15 2026. PAT of Rs 202 crore up 28.7% YoY from Rs 157 crore in Q4 FY25. Revenue Rs 1,848 crore. Analysis inside.<\/p>\n","protected":false},"author":26,"featured_media":90888,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[],"class_list":["post-90115","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"metadata":{"rank_math_internal_links_processed":["1"],"_edit_lock":["1779104983:26"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["842"],"rank_math_seo_score":["81"],"rank_math_focus_keyword":["Alembic Pharmaceuticals Q4"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"],"rank_math_title":["Alembic Pharmaceuticals Q4 FY26: PAT Rs 202 Cr"],"rank_math_description":["Alembic Pharmaceuticals Q4 FY26 results May 15 2026. PAT of Rs 202 crore up 28.7% YoY from Rs 157 crore in Q4 FY25. Revenue Rs 1,848 crore. Analysis inside."],"_thumbnail_id":["90888"],"_edit_last":["26"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["12120"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/05\/18171857\/Alembic-Pharmaceuticals-Q4-FY26-Results.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/90115","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/26"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=90115"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/90115\/revisions"}],"predecessor-version":[{"id":90889,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/90115\/revisions\/90889"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/90888"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=90115"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=90115"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=90115"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}